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Few therapeutic options are available for T790M-negative non-small cell lung cancer (NSCLC) after
failure of primary epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemo-
therapy. This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated
T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-
immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of plat-
inum doublets, TKIs, pemetrexed and nivolumab. The management of advanced EGFR mutation-positive
NSCLC is briefly reviewed herein and the emerging paradigm of episensitization, which contradicts the
long-standing and widely accepted tenet about the immutability of resistance and the futility of ther-
apeutic rechallenge, is introduced as a strategy to avert treatment failure and thereby stave off deteri-
oration and death.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Up to 85% of all lung tumors, the leading cause of cancer mor-
tality worldwide, greater than the combined mortality from can-
cers of the breast, prostate and colon, are classified as nonesmall-
cell lung cancer (NSCLC) [1].
The identification of targetable driver mutations such as EGFR,
KRAS, EML4-ALK and MET has dramatically changed the treatment
landscape for NSCLC. As one of the most commonly altered genes in
lung cancer, epidermal growth factor receptor (EGFR) is mutated in
approximately 17% of tumors in patients with pulmonary adeno-
carcinoma, leading to constitutive activation of the EGFR tyrosine
kinase [2]. Upregulation of EGFR signaling, due to deletions or
amino acid substitutions clustered around the ATP-binding pocket
of the tyrosine kinase domain of EGFR, and present in more than
50% of East Asians, never smokers and women [3] with adenocar-
cinoma histology is correlated with poor responses to PD-1
checkpoint inhibition [4,5]. Despite strikingly high efficacy rates
with EGFR tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, andarter).
Ltd. This is an open access article uafatinib, especially in patients with an activating mutation in exons
18e21 of the EGFR gene, (including an exon 19-deletion and L858R
substitution collectively referred to as EGFRm) the development of
resistance [6] after 10e12 months is nearly inevitable in all tumors
[7].
In about 50% of non-squamous cell patients steric hindrance
from the replacement of a threonine by the bulkier methionine at
the gatekeeper position of the kinase domain (T790M) is thought to
significantly decrease the inhibitory activity of gefitinib, erlotinib
and afatinib, leading to resistance [8]. T790Mmutation is a double-
edged sword because, on the one hand, its emergence limits long-
term treatment with TKIs but, on the other, the mutation is asso-
ciated with indolent progression and a more favorable prognosis
than its mutation negative counterpart [9]. Moreover, in the case of
resistance due to a T790M mutation the third generation T790M
mutant-specific tyrosine kinase inhibitor, osimertinib, based on
data from the Phase II AURA 2 trial and the AURA extension cohort,
is indicated irrespective of previous exposure to an EGFR TKI (The
third generation TKI, rociletinib, is in phase III clinical development)
[10e12]. At progression on osimertinib treatment is generally
platinum doublets for 4e6 cycles with or without bevacizumab
followed by the option of single agent pemetrexed or docetaxel or
erlotinib.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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aggressive tumor phenotype and a worse prognosis; second-line
chemotherapy is the current standard of care [13] (Fig. 1).
This report presents the case of a 71-year-old Asian female never
smoker with TKI, platinum, pemetrexed, and PD-1-resistant EGFR
positive T790M negative NSCLC who received the epi-
immunotherapeutic priming agent RRx-001 in the context of a
clinical trial called TRIPLE THREAT (NCT02489903) [14]; per pro-
tocol on progression of RRx-001 platinum doublets were reintro-
duced. However due to the development of peripheral neuropathy
fromnab-paclitaxel, the patient received carboplatin only, resulting
in a partial response after 4 cycles.2. Case report
This case concerns a 71-year-old Asian female never smoker
diagnosed in 2008 with stage 1B NSCLC adenocarcinoma located in
the left upper lobe for which she underwent a left lobectomy. In
2010 recurrence to the right hila was treated with a wedge resec-
tion and adjuvant carboplatin/taxol for 2 cycles followed by
cisplatin/etoposide and concurrent radiotherapy. In January 2012,
she was diagnosed with metastatic adenocarcinoma of the lung,Fig. 1. Proposed treatment algorithm for patients with EGFRm non-squamepidermal growth factor receptor mutation positive with a deletion
found on exon 19; erlotinib was started with a partial response. In
August 2013 after progression on erlotinib, she began pemetrexed,
which was continued for over a year until September 2014, when
progression was documented. In November 2014 she began nivo-
lumab but progressed after only 3 doses (6 weeks).
On rebiopsy of the tumor in January 2015 the activating deletion
mutation in exon 19 was still present but T790Mmutationwas not,
which led to treatment with the second generation TKI, afatinib, in
February 2015. Due tomultiple episodes of poorly tolerated Grade 3
diarrhea, several dose reductions and interruptions were required,
leading to permanent discontinuation of afatinib in August 2015.
In October 2015 the patient was enrolled on the TRIPLE THREAT
clinical trial (NCT02489903), so-named because patients with
NSCLC, high grade neuroendocrine carcinoma and SCLC previously
treated with platinum doublets are eligible, and received her first
dose of weekly 4mg RRx-001 on December 08, 2015. The first CT
scan at six weeks demonstrated stable disease (increase of
approximately 8%). By twelve weeks she progressed and was star-
ted per protocol on carboplatin and nab-paclitaxel. However, due to
the recurrence of sensory neuropathy, nab-paclitaxel was dis-
continued and only carboplatin was administered at a reducedous NSCLC and T790M positive and T790M negative mutation status.
Fig. 2. The evolution of tumor burden is shown over 3 serial CT scans: 1) on 1/5/15 before starting afatinib 2) after stopping RRx-001 on 1/11/16 due to progression and 3) at the
nadir of tumor regression (34.8% compared to 1/11/16) on 4/7/16 after 4 cycles of reintroduced carboplatin. Taken together the net percentage of tumor reduction from 1/5/15 to 4/
7/16 was 54.6%. Target lesions are circled in red.
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partial response with a tumor reduction of 34.8%. Serial CT scans
over an approximately 1-year timespan demonstrate that a signif-
icant decrease in tumor size occurred as a result of RRx-001 pre-
treatment prior to sequentially reintroduced carboplatin (Fig. 2).
At this time, no further cycles of carboplatin are planned and the
PI is planning to start the patient on gefitinib.3. Discussion & conclusion
Episensitization is a hybrid term coined by Oronsky et al. [15,16]
for a hybrid strategy that involves administration of an epigenetic
therapy such as RRx-001 or hypomethylator, decitabine, or the
histone deacetylase inhibitor (HDAC), vorinostat, to prime tumors
to respond better (or anew) to sequential or concurrent immuno-
or chemotherapy. The current treatment guidelines in the
palliative-intent setting in NSCLC (and most other tumor types)
involve a switch to a different therapy at progression until all lines
are exhausted and a clinical trial or hospice are the only remaining
options. The switch at progression is mandated by the development
of resistance and cross-resistance, which generally prevents a
retrial of formerly tried or similar therapies.
While the literature describes retreatment with TKI inhibitors
after a drug-free interval and/or treatment past RECIST-defined
progression, no clear evidence supports these strategies [17]; in
fact, recent data from the IMPRESS trial [18] (A Study of IRESSA
Treatment Beyond Progression in Addition to Chemotherapy
Versus Chemotherapy Alone), which randomly assigned 265 pa-
tients with disease progression on first-line gefitinib to cisplatin/
pemetrexed plus either gefitinib or placebo suggests inferior sur-
vival in the arm combining chemotherapy with gefitinib (survival
from time of randomization, 14.8 months for the chemotherapy/
gefitinib arm vs. 17.2 months for the chemotherapy/placebo arm).Episensitization, a strategy intended to reverse the multidrug
resistant phenotype in tumors after a priming period with
epigenetic-based therapies, has the potential to render the term
“treatment failure” irrelevant (or at the very least less definitive)
since patients may still benefit from reintroduced first or second
line therapies even after their initial cessation due to progression
[19,20]. In this and other journals, episensitization with RRx-001
has been documented in the context of Phase I and Phase II clin-
ical trials on multiple occasions and in several different metastatic
tumor types such as colorectal, neuroendocrine, SCLC and NSCLC,
which suggests that priming refractory cancer cells with RRx-001
may globally change patterns of resistance and treatment re-
sponses [21e23]. As evidence that the episensitization strategy
may successfully “turn back the clock” on cancer cells, serial CT
scans over 11 months in the patient of this case report demon-
strated a marked reduction in tumor size.
The absence of the T790M mutation in EGFRþ non-squamous
NSCLC is a harbinger for a more rapid progression of disease and
shorter survival. Given the dearth of viable treatment options after
failure of first and second generation EGFR TKIs and platinum
doublets in this EGFRþ subset, RRx-001 priming may lead to
renewed sensitivity to chemotherapy (and possibly immuno-
therapy) with partial responses and increased overall survival, all of
which occurred in the pan-refractory patient of this case report.Conflict of interest
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observed is funded by EpicentRx, Inc.References
[1] G. D'Addario, M. Früh, M. Reck, P. Baumann, W. Klepetko, E. Felip, ESMO
C.A. Carter et al. / Respiratory Medicine Case Reports 18 (2016) 62e65 65guidelines working group. Metastatic non-small-cell lung cancer: ESMO
clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol.
21 (Suppl. 5) (2010 May) v116e119.
[2] R. Rosell, T. Moran, C. Queralt, et al., Spanish lung cancer group. Screening for
epidermal growth factor receptor mutations in lung cancer, N. Engl. J. Med.
361 (10) (2009) 958e967.
[3] F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh,
S. Thongprasert, et al., Erlotinib in previously treated non-small-cell lung
cancer, N. Engl. J. Med. 353 (2005) 123e132.
[4] L. Paz-Ares, L. Horn, H. Borghaei, et al., Phase III, randomized trial (CheckMate
057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous
cell (non-SQ) non-small cell lung cancer (NSCLC) [ASCO abstract LBA109],
J. Clin. Oncol. 33 (2015).
[5] B. Melosky, Q. Chu, R. Juergens, N. Leighl, D. McLeod, V. Hirsh, Pointed prog-
ress in second-line advanced non-small-cell lung cancer: the rapidly evolving
field of checkpoint inhibition, J. Clin. Oncol. (2016 Feb 16). JCO638049.
[6] L.V. Sequist, J. von Pawel, E.G. Garmey, et al., Randomized phase II study of
erlotinib plus tivantinib versus erlotinib plus placebo in previously treated
non-small-cell lung cancer, J. Clin. Oncol. 29 (2011) 3307e3315.
[7] A. Michalczyk, S. Klüter, H.B. Rode, J.R. Simard, C. Grütter, M. Rabiller, D. Rauh,
Structural insights into how irreversible inhibitors can overcome drug resis-
tance in EGFR, Bioorg. Med. Chem. 16 (2008) 3482e3488.
[8] J. Engel, J. Lategahn, D. Rauh, Hope and disappointment: covalent inhibitors to
overcome drug resistance in non-small cell lung cancer, ACS Med. Chem. Lett.
7 (1) (2016) 2e5.
[9] A. Hata, N. Katakami, H. Yoshioka, J. Takeshita, K. Tanaka, S. Nanjo, S. Fujita,
R. Kaji, Y. Imai, K. Monden, T. Matsumoto, K. Nagata, K. Otsuka, R. Tachikawa,
K. Tomii, K. Kunimasa, M. Iwasaku, A. Nishiyama, T. Ishida, Y. Nishimura,
Rebiopsy of non-small cell lung cancer patients with acquired resistance to
epidermal growth factor receptor-tyrosine kinase inhibitor: comparison be-
tween T790M mutation-positive and mutation-negative populations, Cancer
119 (24) (2013 Dec 15) 4325e4332.
[10] A. Yver, Osimertinib (AZD9291)da science-driven, collaborative approach to
rapid drug design and development, Ann. Oncol. (March 8, 2016) 1e6, http://
dx.doi.org/10.1093/annonc/mdw129.
[11] Park K, Tan E, Zhang L, et al. Afatinib (A) vs gefitinib (G) as first-line treatment
for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring
activating EGFR mutations: results of the global, randomized, open-label,
Phase IIb trial LUX-Lung 7 (LL7). Presented at: 2015 ESMO Asia Congress;
Singapore; December 18-21, 2015. Abstract LBA2.
[12] Yang JC, Ahn M, Ramalingam SS, et al. AZD9291 in pre-treated T790M positiveadvanced NSCLC: AURA study Phase II extension cohort. Presented at: 16th
World Conference on Lung Cancer; September 6-9; Denver, CO. Abstract 943.
[13] Z. Piotrowska, L.V. Sequist, Continued EGFR inhibition with postprogression
chemotherapy: where do we stand? Oncologist 20 (11) (2015 Nov)
1230e1232.
[14] H. Zhao, S. Ning, J. Scicinski, B. Oronsky, S.J. Knox, D.M. Peehl, Epigenetic ef-
fects of RRx-001: a possible unifying mechanism of anticancer activity,
Oncotarget 6 (41) (2015 Dec 22) 43172e43181.
[15] B.T. Oronsky, A.L. Oronsky, M. Lybeck, N.C. Oronsky, J.J. Scicinski, C. Carter,
G.R. Fanger, T.R. Reid, in: G. Egger (Ed.), Episensitization: a New Word for a
New Concept, in Drug Discovery in Cancer Epigenetics, 2016.
[16] B. Oronsky, N. Oronsky, S. Knox, G. Fanger, J. Scicinski, Episensitization:
therapeutic tumor resensitization by epigenetic agents: a review and reas-
sessment, Anticancer Agents Med. Chem. 14 (8) (2014) 1121e1127.
[17] E.A. Kuczynski, D.J. Sargent, A. Grothey, R.S. Kerbel, Drug rechallenge and
treatment beyond progressiondimplications for drug resistance, Nat. Rev.
Clin. Oncol. 10 (2013) 571e587.
[18] J.C. Soria, Y.L. Wu, K. Nakagawa, S.W. Kim, J.J. Yang, M.J. Ahn, J. Wang, J.C. Yang,
Y. Lu, S. Atagi, S. Ponce, D.H. Lee, Y. Liu, K. Yoh, J.Y. Zhou, X. Shi, A. Webster,
H. Jiang, T.S. Mok, Gefitinib plus chemotherapy versus placebo plus chemo-
therapy in EGFR-mutation-positive non-small-cell lung cancer after progres-
sion on first-line gefitinib (IMPRESS): a phase 3 randomised trial, Lancet
Oncol. 16 (8) (2015 Aug) 990e998.
[19] B.T. Oronsky, A.L. Oronsky, M. Lybeck, N.C. Oronsky, J.J. Scicinski, C. Carter,
R.M. Day, J.F. Rodriguez Orengo, M. Rodriguez-Torres, G.F. Fanger, T.R. Reid,
Episensitization: defying time's arrow, Front. Oncol. 5 (2015 Jun 11) 134.
[20] J. Strauss, W.D. Figg, Epigenetic approaches to overcoming chemotherapy
resistance, Lancet Oncol. 16 (9) (2015) 1013e1015.
[21] C.A. Carter, B.T. Oronsky, S.Z. Caroen, J.J. Scicinski, A. Degesys, M.M. Kim,
A.L. Oronsky, H. Lybeck, P. Cabrales, N. Oronsky, T. Reid, J. Roswarski,
C. Brzezniak, RRx-001 in refractory small-cell lung carcinoma: a case report of
a partial response after a third reintroduction of platinum doublets, Case Rep.
Oncol. 9 (1) (2016 Mar 11) 171e176.
[22] T. Reid, S. Dad, R. Korn, B. Oronsky, S. Knox, J. Scicinski, Two Case reports of
resensitization to previous chemotherapy with the novel hypoxia-activated
hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer
patients, Case Rep. Oncol. 7 (1) (2014 Jan 24) 79e85.
[23] C.A. Carter, B.T. Oronsky, S.Z. Caroen, J.J. Scicinski, P. Cabrales, T. Reid,
A. Degesys, J. Jenkins, C. Brzezniak, Partial response to platinum doublets in
refractory EGFR-positive non-small cell lung cancer patients after RRx-001:
evidence of episensitization, Case Rep. Oncol. 9 (1) (2016 Jan 28) 62e67.
